LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
Ontology highlight
ABSTRACT: The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions
DISEASE(S): Egfri Induced Acneiform Lesions
PROVIDER: 2367764 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA